From Curious Learner to Pioneer: Dr. Jie Chen’s Medical Evolution

From Curious Learner to Pioneer: Dr. Jie Chen’s Medical Evolution

2024.10.16
As we step further into the 21st century, the field of medicine has undergone tremendous changes. Among the many advancements, a generation of compassionate and skilled doctors has emerged, dedicated to the wellbeing of their patients and their nation. The phrase "a doctor's heart is like a parent's" perfectly captures this essence. In the Oncology Frontier series "In Conversation," we reflect on the past with renowned doctors, exploring the highs and lows of their medical journeys. In this edition, we are honored to have Dr. Jie Chen from Fudan University Shanghai Cancer Center share her story. Over the past 30 years, she has remained dedicated to her mission. With five major career transitions, she has continually embraced challenges, breaking new ground where none existed. In the virtually untouched field of neuroendocrine tumors (NEN) in China, she laid the foundation for the discipline and paved the way for future advancements.
Plerixafor-Based Mobilization and Increased Mononuclear Cell Counts: Risk Factors for Engraftment Syndrome Post-Autologous Hematopoietic

Plerixafor-Based Mobilization and Increased Mononuclear Cell Counts: Risk Factors for Engraftment Syndrome Post-Autologous Hematopoietic

2024.10.16
In June 2024, Blood Science published a significant study led by Dr. Xiaohui Zhang and colleagues from the Peking University People's Hospital, focusing on the incidence and risk factors of engraftment syndrome (ES) following autologous hematopoietic stem cell transplantation (ASCT) in the era of plerixafor-based mobilization. ASCT remains a critical therapy for hematologic malignancies, particularly in lymphoma and plasma cell disease, despite advancements in other treatments. However, ES, characterized by non-infectious fever, skin rash, diarrhea, and other clinical manifestations, remains a common and concerning complication post-ASCT.
Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

2024.10.16
In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is a challenging hematological malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Despite significant advances in treatment, many patients experience relapse or develop resistance to existing therapies, necessitating new and more effective approaches.
Pomalidomide Enhances CAR-T Therapy Effectiveness in Hematological Malignancies: A Promising Synergy

Pomalidomide Enhances CAR-T Therapy Effectiveness in Hematological Malignancies: A Promising Synergy

2024.10.16
Relapsed and refractory multiple myeloma (R/R MM) and B-cell leukemia/lymphoma with extramedullary disease (EMD) represent some of the most formidable challenges in hematology. These conditions often carry a bleak prognosis due to their resistance to conventional therapies and the complex nature of extramedullary disease, where cancer cells spread outside the bone marrow. Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment landscape for these malignancies, offering hope where few options existed. However, even with CAR-T cell therapy, patients with EMD have experienced limited success, highlighting the need for innovative approaches to improve outcomes.
Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

Subcutaneous Daratumumab in Chinese Patients with Relapsed/Refractory Multiple Myeloma: A Phase 1 Study

2024.10.15
In April 2024, the journal Blood Science published an important study led by Dr. Gang An and colleagues from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, investigating the use of subcutaneous daratumumab in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). Multiple myeloma is a challenging hematological malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Despite significant advances in treatment, many patients experience relapse or develop resistance to existing therapies, necessitating new and more effective approaches.
Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive

Breaking the Barrier of Immunotherapy Consolidation, ALK-TKI Combined with CRT Might Transform the Standard Treatment for Unresectable ALK-Positive

2024.10.15
The American Society for Radiation Oncology (ASTRO) Annual Meeting took place in Washington, D.C., from September 29,2024 to October 2,2024. As one of the most prestigious annual events in radiation oncology, ASTRO offers a platform to share the latest advances, focusing on radiotherapy as a primary treatment for various cancers, alongside key updates in technology and basic research.
Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer

Dr. Lorusso comments on the OS results of KEYNOTE-A18 study: There is a new standard for the treatment of locally advanced high-risk cervical cancer

2024.10.14
The data of the KEYNOTE-A18 study disclosed at the Presidential Symposium I of the 2024 ESMO Congress shows that the overall survival (OS) of newly diagnosed patients with locally advanced cervical cancer who received pembrolizumab and concurrent chemoradiotherapy (CRT) is significantly improved (abstract number 709O). The 36-month OS rate of pembrolizumab + concurrent CRT treatment is 82.6%, and the 36-month OS rate of placebo + concurrent CRT treatment is 74.8% (hazard ratio [HR]=0.67; 95% confidence interval [CI]: 0.50–0.90; P=0.0040). The median OS has not been reached in both treatment groups. The survival benefit is consistent in all prespecified subgroups. At a median follow-up of 29.9 months, the 36-month progression-free survival (PFS) rates of the pembrolizumab group and the placebo group are 69.3% and 56.9%, respectively, and the median PFS is still NR (HR=0.68; 95% CI: 0.56-0.84). The incidences of grade ≥3 treatment-related adverse events in the two treatment groups are 69.1% and 61.3%, respectively. Quality of life (QOL) is not affected. At week 36, using the EORTC QLQ-C30 quality of life index questionnaire, no clinically significant differences between groups are reported.
ESMO 2024丨Dr. González-Martín interprets the final analysis results of the PRIMA/ENGOT-ov26/GOG-3012 study

ESMO 2024丨Dr. González-Martín interprets the final analysis results of the PRIMA/ENGOT-ov26/GOG-3012 study

2024.10.14
Dr. Antonio González-Martín from the Cancer Center Clínica Universidad de Navarra in Spain presented the results of the phase III PRIMA/ENGOT-OV26/GOG-3012 study (abstract number LBA29) at the 2024 ESMO Congress. For patients with advanced ovarian cancer with homologous recombination deficiency (HRd), the possibility of progression-free survival after treatment with niraparib is twice that of placebo, although the study did not report long-term overall survival (OS) benefit. Oncology Frontier invited Dr.Antonio González-Martín on site to analyze the clinical significance of this research finding.